Table 2.
Spontaneous reperfusion (n=98) | Thrombolysis (n=1163) | Primary PTCA (n=102) | No reperfusion (n=1017) | p Value | |
Recurrent ischaemia | 34 (35%) | 196 (17%) | 12 (12%) | 161 (16%) | <0.001 |
Heart failure | 12 (12%) | 151 (13%) | 21 (21%) | 197 (19%) | <0.001 |
Cardiogenic shock | 1 (1%) | 33 (3%) | 14 (14%) | 69 (7%) | <0.0001 |
VT or VF | 10 (10%) | 174 (15%) | 31 (30%) | 112 (11%) | <0.0001 |
Recurrent AMI | 3 (3%) | 37 (3%) | 2 (2%) | 18 (2%) | 0.2 |
In-hospital treatment | |||||
Aspirin | 90 (92%) | 1100 (95%) | 99 (97%) | 869 (85%) | <0.0001 |
β Blockers | 58 (59%) | 703 (60%) | 44 (43%) | 512 (50%) | <0.0001 |
ACE inhibitors | 42 (43%) | 602 (52%) | 62 (61%) | 492 (48%) | 0.02 |
Heparin | 89 (91%) | 970 (83%) | 90 (88%) | 814 (80%) | 0.006 |
In-hospital procedures | |||||
Coronary angiography | 51 (52%) | 434 (37%) | 102 (100%) | 305 (30%) | <0.0001 |
PTCA | 32 (33%) | 244 (21%) | 102 (100%) | 140 (14%) | <0.0001 |
CABG | 11 (11%) | 61 (5%) | 3 (3%) | 55 (5%) | 0.05 |
Procedures within 30 days | |||||
Coronary angiography | 66 (67%) | 585 (50%) | 102 (100%) | 441 (43%) | <0.0001 |
PTCA | 40 (41%) | 303 (26%) | 102 (100%) | 180 (18%) | <0.0001 |
CABG | 16 (16%) | 105 (9%) | 6 (6%) | 106 (10%) | 0.05 |
ACE, angiotensin converting enzyme; AMI, acute myocardial infarction; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; VF, ventricular fibrillation; VT, ventricular tachycardia.